Edrecolomab

Edrecolomab (MAb17-1A) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and on various carcinomas. Preliminary studies had shown promise of a possible use in patients with colorectal carcinoma. However, when put to a phase III study (2,761 patients) it did not provide any benefit when compared to conventional chemotherapeutic agents ^[1]. It is important to mention that edrecolomab was well tolerated and as such research has now concentrated on whether it can be of any use in other forms of cancer.

References

1. ^ Punt CJ et al, Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. The Lancet, Volume 360, Issue 9334, Pages 671-677 [1]